Home / Research Articles Hub / Pembrolizumab in combination with gemcitabine and...
🧬 Medicine & Biology OpenAlex

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

📅 Published: April 16, 2023 👤 Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. 📖 The Lancet 📊 1,008 citations
AI-Generated Summary

This research explores Pembrolizumab in combination with gemcitabine and cisplatin..., contributing new insights to the field of Medicine & Biology.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

Key Findings
  • 1 Research demonstrates significant advances in patient outcome data
  • 2 Study provides new evidence regarding clinical efficacy results
  • 3 Findings open new directions for biological mechanism insights
Why It Matters

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source:

Read Full Paper at OpenAlex
More Medicine & Biology Papers ← Back to Hub 📚 Learning Hub